- Home
- TENX vs IGC Comparison
TENX vs IGC Comparison
Compare TENX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- IGC
- Stock Information
- Founded
- TENX 1967
- IGC 2005
- Country
- TENX United States
- IGC United States
- Employees
- TENX N/A
- IGC N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- IGC Health Care
- Exchange
- TENX Nasdaq
- IGC Nasdaq
- Market Cap
- TENX 21.6M
- IGC 20.2M
- IPO Year
- TENX N/A
- IGC N/A
- Fundamental
- Price
- TENX $6.06
- IGC $0.31
- Analyst Decision
- TENX Strong Buy
- IGC Strong Buy
- Analyst Count
- TENX 3
- IGC 2
- Target Price
- TENX $16.00
- IGC $3.88
- AVG Volume (30 Days)
- TENX 11.9K
- IGC 213.7K
- Earning Date
- TENX 05-14-2025
- IGC 06-23-2025
- Dividend Yield
- TENX N/A
- IGC N/A
- EPS Growth
- TENX N/A
- IGC N/A
- EPS
- TENX N/A
- IGC N/A
- Revenue
- TENX N/A
- IGC $1,236,000.00
- Revenue This Year
- TENX N/A
- IGC N/A
- Revenue Next Year
- TENX N/A
- IGC $16.45
- P/E Ratio
- TENX N/A
- IGC N/A
- Revenue Growth
- TENX N/A
- IGC 1.65
- 52 Week Low
- TENX $2.77
- IGC $0.25
- 52 Week High
- TENX $7.89
- IGC $0.55
- Technical
- Relative Strength Index (RSI)
- TENX 55.80
- IGC 48.79
- Support Level
- TENX $5.60
- IGC $0.30
- Resistance Level
- TENX $6.31
- IGC $0.33
- Average True Range (ATR)
- TENX 0.27
- IGC 0.02
- MACD
- TENX -0.01
- IGC -0.00
- Stochastic Oscillator
- TENX 63.31
- IGC 13.20
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.